ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
503
views
0
references
Top references
cited by
279
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
16
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,278
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Trastuzumab--mechanism of action and use in clinical practice.
Author(s):
Clifford Hudis
Publication date:
2007-07-05
Journal:
The New England journal of medicine
Keywords:
Antibodies, Monoclonal
,
adverse effects
,
pharmacology
,
therapeutic use
,
Antibodies, Monoclonal, Humanized
,
Antineoplastic Agents
,
Breast Neoplasms
,
drug therapy
,
metabolism
,
Chemotherapy, Adjuvant
,
Humans
,
Receptor, Epidermal Growth Factor
,
Receptor, ErbB-2
,
analysis
,
drug effects
,
immunology
,
Signal Transduction
Read this article at
ScienceOpen
Publisher
PubMed
Further versions
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Drug_transporters
Author and article information
Journal
DOI::
10.1056/NEJMra043186
PubMed ID::
17611206
ScienceOpen disciplines:
Chemistry
Keywords:
Antibodies, Monoclonal
,
adverse effects
,
pharmacology
,
therapeutic use
,
Antibodies, Monoclonal, Humanized
,
Antineoplastic Agents
,
Breast Neoplasms
,
drug therapy
,
metabolism
,
Chemotherapy, Adjuvant
,
Humans
,
Receptor, Epidermal Growth Factor
,
Receptor, ErbB-2
,
analysis
,
drug effects
,
immunology
,
Signal Transduction
Data availability:
ScienceOpen disciplines:
Chemistry
Keywords:
Antibodies, Monoclonal
,
adverse effects
,
pharmacology
,
therapeutic use
,
Antibodies, Monoclonal, Humanized
,
Antineoplastic Agents
,
Breast Neoplasms
,
drug therapy
,
metabolism
,
Chemotherapy, Adjuvant
,
Humans
,
Receptor, Epidermal Growth Factor
,
Receptor, ErbB-2
,
analysis
,
drug effects
,
immunology
,
Signal Transduction
Comments
Comment on this article
Sign in to comment
Related Documents Log
scite_
Similar content
2,278
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer
Authors:
Ruveyda Ayasun
,
Ilyas Sahin
miR-135b-5p enhances the sensitivity of HER-2 positive breast cancer to trastuzumab via binding to cyclin D2
Authors:
Zhilan Li
,
Yiyu Qin
,
Peihong Chen
…
Efficacy of a novel interstitial lung disease monitoring program in breast cancer patients undergoing treatment with trastuzumab-deruxtecan
Authors:
Julie Williamson
,
Kristen Kelley
,
Mary Beth Scholand
…
See all similar
Cited by
699
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Authors:
A Goldhirsch
,
W. C. Wood
,
A S Coates
…
Kinase-targeted cancer therapies: progress, challenges and future directions
Authors:
Khushwant S Bhullar
,
Naiara Lagarón
,
Eileen M. McGowan
…
Targeting cellular metabolism to improve cancer therapeutics
Authors:
Y. Zhao
,
E B Butler
,
Tricia Tan
See all cited by
Version 1
Version 1
Version 1